Fig. 1

Evidence network for ITCs of BVL^a

^aTreatment nodes are sized proportionally to sample sizes, and connections between treatment nodes are indicated with line thickness proportional to the number of trials informing the connection. All connections were incorporated in the MBMA analysis, whereas only the nodes and trials shown in boldface were included in the NMA (since DMT dosages that were not of interest were excluded from the NMA)

Abbreviations: 24W = every 24 weeks, 2W = every two weeks, 4W = every four weeks, ALE = alemtuzumab, BID = twice daily, BVL = brain volume loss, CI = confidence interval, DMF = dimethyl fumarate, FIN = fingolimod, GA = glatiramer acetate, IFNβ = interferon β, NAT = natalizumab, OFA = ofatumumab, OZA = ozanimod, PBO = placebo, PEG = peginterferon β-1a, PON = ponesimod, Q2W = every two weeks, QD = once daily, QOD = every other day, QW = once weekly, TER = teriflunomide, TID = three times daily